STEP 12, a phase 3b trial in 242 Chinese adults with overweight or obesity, found once-weekly semaglutide 2.4 mg reduced bodyweight by 9.9 percentage points more than placebo after 44 weeks, using locally defined BMI thresholds between 24 and 30 kg/m². The responder rate for at least 5% weight loss…
Once-weekly semaglutide 2.4 mg reduced bodyweight by an estimated 9.9 percentage points more than placebo in Chinese adults with overweight or obesity, the completed phase 3b STEP 12 trial showed. The estimated treatment difference was -9.9 percentage points 95% CI -11.8 to -8.0; p<0.0001 . Mean percentage change in bodyweight was -12.1% SE 0.6 in the semaglutide group versus -2.2% SE 0.8 in the placebo group after 44 weeks of treatment combined with lifestyle intervention.
The trial randomised 242 participants at 19 sites across mainland China and Taiwan, using locally defined BMI thresholds that sit below the global cutoffs applied in prior semaglutide indications. Overweight was defined as BMI 24 to <28 kg/m² with at least one weight-related comorbidity, and obesity as BMI 28 to <30 kg/m², with or without type 2 diabetes. The global criteria for the existing indication set obesity at BMI ≥30 kg/m² and overweight with weight-related comorbidities at ≥27 kg/m².
A significantly higher proportion of treated participants reached the coprimary bar of at least 5% bodyweight reduction: 80.5% in the semaglutide group versus 24.4% in the placebo group, an odds ratio of 14.8 95% CI 7.4 to 29.6; p<0.0001 .
STEP 12 is registered at ClinicalTrials.gov as NCT06041217, with a screening period that ran from September 15, 2023 to May 7, 2025. The design is randomised, double-blind, placebo-controlled, multicentre, two-armed, and parallel-group, in phase 3b.
Investigators screened 254 participants and randomly assigned 242 of them in a 2:1 ratio: 161 66.5% to semaglutide 2.4 mg once weekly and 81 33.5% to placebo. The randomised population included 121 female participants 50.0% and 47 participants with type 2 diabetes 19.4% . All participants received lifestyle intervention alongside the study drug.
The two coprimary endpoints were the percentage change in bodyweight and the proportion of participants achieving at least 5% bodyweight reduction, and both were met. Adverse events were more common with the drug than with placebo: 141 of 161 participants 87.6% in the semaglutide group reported adverse events versus 61 of 81 75.3% in the placebo group. Gastrointestinal disorders were the most common adverse event category.
The randomised, double-blind, placebo-controlled structure is the strongest design available for estimating the causal effect of a drug on a measured outcome. Random allocation and concealed assignment mean the only systematic difference between the two arms at baseline is the treatment, so the weight change difference between groups can be attributed to semaglutide rather than to patient characteristics or the lifestyle intervention common to both arms.
The phase 3b label is itself informative. Trials in this phase are run after or alongside the main development program to confirm benefit in a defined population or regional setting, and they often underpin regulatory submissions in new territories. Here the population is defined by Chinese and Taiwanese criteria. The lower BMI cutoffs reflect a substantial body of epidemiology showing that East Asian populations accumulate cardiometabolic risk at lower body mass index than European populations, so a drug evaluated against global thresholds that start at 27 kg/m² for overweight and 30 kg/m² for obesity leaves a gap for patients whose risk is already increased in the 24 to 30 kg/m² range. STEP 12 was designed to close that gap.
What the design does not provide is equally clear. There is no active comparator arm, so the results do not rank semaglutide against other weight-management drugs. There is no reported off-treatment follow-up, so durability after discontinuation is not addressed. And a single 44-week trial of 242 participants cannot detect rare safety signals or effects on hard outcomes such as cardiovascular events.
Semaglutide is a synthetic 31-amino-acid analogue of human glucagon-like peptide-1, the incretin hormone secreted by intestinal L cells in response to food. Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4, so the analogue has been engineered for survival. A substitution at position 8 blocks that cleavage, and acylation with a fatty acid chain allows stable binding to albumin, extending the half-life to about one week and enabling once-weekly dosing.
GLP-1 receptors are expressed on pancreatic beta cells, in the gastrointestinal tract, and in the brain, including the hypothalamus. The weight loss produced by GLP-1 receptor agonism is largely a central effect. The peptide reaches the brain at circumventricular organs and modulates appetite circuits in the arcuate nucleus, including POMC/CART neurons that suppress hunger, while delayed gastric emptying adds a satiety signal from the gut. These pathways are conserved across populations, which is why efficacy observed in Western cohorts was expected to translate, but translation had to be demonstrated.
The 2.4 mg once-weekly dose is the high-dose, weight-management formulation of semaglutide, above the doses used for glycemic control in type 2 diabetes. Weight loss responds steeply to dose in this class, and the adverse event pattern in STEP 12 is consistent with that pharmacology. Gastrointestinal effects, of which nausea is the most familiar example in this drug class, are on-target consequences of receptor activation, which is why they dominate the adverse event profile and why dose escalation is a clinical standard.
The Peptide Atlas registry holds 668 registered clinical trials for semaglutide, with a phase breakdown listing four Phase 2 trials, four Phase 4 trials, and one Phase 3 trial. Ten trials carry a recruiting status. STEP 12 is one of the more targeted of these: a confirmatory phase 3b study in a specific regional population rather than a broad investigation of new disease areas.
The named trials on file show how wide the program has become. NCT07586150 is testing personalized pharmaco-lifestyle interventions in severe mental illness, NCT07430332 is studying a GLP-1 receptor agonist in stage 1 type 1 diabetes, and NCT07614412 is investigating Shingrix and GLP-1 agonism for beta-cell preservation in recent-onset type 1 diabetes. NCT07462663 is a pilot trial of multimodal pre-surgical optimization versus standard surgery in obesity and early-stage endometrial cancer, NCT07027969 is evaluating metabolic surgery for atrial fibrillation elimination, and NCT06977438 is testing GLP-1 plus lifestyle in childhood obesity.
The indexed literature tracks the same expansion. Peptide Atlas lists 197 PubMed papers on semaglutide, including a systematic review and meta-analysis of long-term safety and renal outcomes in non-diabetic obesity with chronic kidney disease or hypertension PMID 42340790 , a meta-analysis of weight-lowering drugs and natural female fertility PMID 42307450 , a randomized clinical trial of semaglutide and effort-based decision-making in major depressive disorder PMID 42054055 , the STRIDE trial in peripheral artery disease and diabetes PMID 41780559 , and a scoping review of retinal vascular events PMID 42348481 .
For clinicians in mainland China and Taiwan, STEP 12 supplies randomised evidence at the BMI thresholds that define overweight and obesity in their own populations. The distinction is more than terminological. Patients who enter treatment at BMI 28 to <30 kg/m², below the global obesity cutoff, achieved a 12.1% mean weight reduction, showing that the efficacy of the peptide is not conditional on the higher body weights studied in global development programs.
For researchers, the responder endpoint carries the clinical meaning. An odds ratio of 14.8 for reaching at least 5% weight loss is a large effect, and the demographic composition of the trial, roughly half female and one in five with type 2 diabetes, gives the results direct relevance to the mixed clinic population that manages obesity alongside other metabolic conditions.
For the peptide supply chain, STEP 12 is another demand signal for a molecule that is already among the most heavily manufactured peptide products. The clinical expansion visible in the registry increases the stakes for quality control in research-grade and compounded semaglutide. Peptide Atlas holds eight third-party laboratory purity test results for semaglutide on file, and the highest observed purity is 99.979%. That benchmark shows the molecule can be manufactured to very high standards, and it underscores why independent analytical verification matters for bulk peptide purchased for research or clinical use. The reference page at https://peptideatlas.co/peptides/semaglutide consolidates the trial registry, the literature index, and the purity records for this product.
The STEP 12 results, as currently reported, carry the constraints of abstract-level disclosure. The full methodology and detailed results are not yet available, so the statistical analysis plan, the handling of missing data, and the exact definition of the analysis population cannot be independently assessed. The screening count illustrates the point: 254 participants were screened but only 242 were randomly assigned, and the reason 12 were excluded is not stated.
Several clinical questions remain open. The specific gastrointestinal adverse events and their severity distribution have not been described, so the tolerability burden of the 2.4 mg dose in this population is not yet quantified beyond the aggregate adverse event rates. Subgroup results have not been reported, leaving unknown whether efficacy and safety differed between the 47 participants with type 2 diabetes and the rest of the cohort. Durability after discontinuation is unresolved, and direct comparison with the STEP trials in non-Chinese populations has not been published, so it is not yet possible to say whether the effect size is specific to this population or consistent with the drug's established profile.
Each gap has a clear resolution. Full publication of STEP 12 would settle the methodology, the exclusion count, and the gastrointestinal event breakdown. Subgroup analyses by diabetes status would show whether the effect is uniform across metabolic states. An extension or withdrawal study would answer the durability question, and a pooled analysis across the STEP program would locate these results within the global evidence base. For now, the clinical message is direct: the peptide produced large, statistically significant weight loss in this population, and the safety signal is consistent with what is known about the drug.
Peptides referenced: Semaglutide, Glucagon, GLP-1.
Related reading: Real-world tirzepatide: 68% persist, 55% adherent, 10.5% weight loss, Semaglutide Slows Rise in Dementia Risk Signature in SELECT Analysis, Why Weight Returns After GLP-1 Agonist Therapy Is Stopped, UK first in Europe to approve Eli Lilly oral GLP-1 orforglipron.